Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2024-04-20 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a new "research evaluation agreement regarding BAN2802" between BioArctic and Eisai. This type of announcement, detailing a new strategic partnership, drug development milestone, or corporate transaction (like licensing or research agreements), does not fit neatly into the specific financial reporting categories (10-K, IR, ER, DIV, etc.). It is a general corporate update. Since it is not a formal regulatory filing like a 10-K or a specific financial report, and it is not an announcement about the publication of another report (RPA), the most appropriate general category for significant corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous official announcements, especially those related to material non-public information under market abuse regulations (as indicated by the closing statement).
2024-04-20 English
BioArctic och Eisai ingår forskningsutvärderingsavtal avseende BAN2802
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a new research evaluation agreement between BioArctic and Eisai regarding a drug candidate (BAN2802). It details the terms of the collaboration, mentions existing successful collaboration (Leqembi), and includes standard boilerplate language about forward-looking statements and contact information. Crucially, the final paragraph states: "Denna information är sådan information som BioArctic AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is information that BioArctic AB (publ) is required to disclose pursuant to the EU's Market Abuse Regulation.) This strongly indicates a mandatory regulatory disclosure, but it is not a full financial report (10-K, IR) or a specific corporate action filing like a dividend notice or director dealing. Since it is a general, mandatory announcement that doesn't fit the specific categories like ER (Earnings Release) or CAP (Capital/Financing Update), the most appropriate general regulatory filing category is RNS (Regulatory Filings), which serves as the fallback for miscellaneous regulatory announcements.
2024-04-20 Swedish
Kallelse årsstämma 2024 BioArctic AB (publ)
AGM Information Classification · 1% confidence The document is titled 'KALLELSE TILL ÅRSSTÄMMA I BIOARCTIC AB (PUBL)' which translates to 'NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)'. It details the date, time, location, registration procedures, and the full proposed agenda for the meeting, including items like election of board members, approval of financial statements, and remuneration proposals. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). The code for AGM-related materials is AGM-R.
2024-04-19 Swedish
Notice of Annual General Meeting in BioArctic AB (publ)
AGM Information Classification · 1% confidence The document explicitly states, "The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Wednesday on 22 May 2024" and is titled "NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)". It details the procedures for participation, voting, proxy submission, and presents the proposed agenda for the meeting, which includes items typical of an AGM (election of directors, remuneration, approval of results). This content directly corresponds to the purpose of an Annual General Meeting (AGM) notice/materials.
2024-04-19 English
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 1% confidence FY 2023
2024-04-18 Swedish
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s disease to the U.S. FDA completed
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces the completion of a submission (sBLA for Leqembi) to the U.S. FDA. It details clinical trial data, regulatory designations (Fast Track, Breakthrough Therapy), and collaboration agreements. This format—a formal announcement of a significant corporate/regulatory event, often released to the public via press wire services—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about regulatory progress rather than a comprehensive financial report (like 10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or RNS if it's purely regulatory news. Given the context of major drug development milestones being announced via press release, ER is often used for key operational updates, but RNS is the most appropriate general regulatory announcement category when it doesn't fit other specific financial reports. However, many companies use press releases for major operational/regulatory updates that are not strictly quarterly earnings. Since the document is a detailed announcement of a regulatory submission and clinical progress, and it concludes with a statement about being obliged to disclose information under the EU Market Abuse Regulation, it functions as a significant regulatory disclosure. Given the options, and since it is not a full financial report, a general Regulatory Filing (RNS) is the safest classification for a material, non-earnings-specific press release about regulatory action. If this were released alongside quarterly results, it might be part of the ER package, but standing alone, RNS is suitable. Upon review, the content is a major operational/regulatory update, which often falls under RNS, but sometimes companies issue these as standalone press releases that are not strictly 'Earnings Releases' (ER). Since it is a formal announcement of a regulatory submission, RNS is the most accurate general regulatory category.
2024-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.